皮加 曹冠柏 刘先齐

    【摘要】 近年来，以程序性死亡受体1(PD-1)抗体、程序性死亡配体1(PD-L1)抗体和细胞毒性T淋巴细胞相关抗原4(CTLA-4)抗体为代表的免疫检查点抑制剂(ICIs)彻底改变了肿瘤治疗。然而，伴随着涉及多个器官的免疫相关不良反应。肝脏不断暴露于外来抗原，已经进化出很高的免疫耐受能力。本文主要综述与免疫介导的肝炎相关的CTLA-4、ICIs、肝脏免疫耐受及免疫介导的肝炎发生机制的研究进展。

    【关键词】 免疫介导的肝炎 免疫治疗 免疫检查点抑制剂

    Research Progress on Immune-mediated Hepatitis/PI Jia， CAO Guanbai， LIU Xianqi. //Medical Innovation of China， 2024， 21(13)： -172

    [Abstract] In recent years， immune checkpoint inhibitors (ICIs) represented by antibodies against programmed death receptor 1 (PD-1)， programmed death ligand 1 (PD-L1)， and cytotoxic T lymphocyte associated antigen 4 (CTLA-4) have completely revolutionized tumor therapy. However， it is accompanied by immune related adverse reactions involving multiple organs. The liver is constantly exposed to foreign antigens and has evolved a high immune tolerance. This article mainly reviews the research progress on CTLA-4， ICIs， liver immune tolerance， and immune mediated hepatitis mechanisms related to immune mediated hepatitis.

    [Key words] Immune-mediated hepatitis Immunotherapy Immune checkpoint inhibitors ......